High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study

Yasuhiro Ryuno1†, Takanori Abe1†, Misaki Iino1, Satoshi Saito1, Tomomi Aoshika1, Tomohiro Oota1, Mitsunobu Igari1, Ryuta Hirai1, Yu Kumazaki1, Kyoichi Kaira2, Hiroshi Kagamu2, Hironori Ishida3, Shin‑ei Noda1 and Shingo Kato1*

Abstract
Background: This retrospective study was performed to evaluate the efficacy and toxicity of high-dose stereotactic body radiotherapy (SBRT) using a CyberKnife® for patients with stage I peripheral non-small cell lung cancer (NSCLC).

Methods: Ninety-six patients with stage I peripheral NSCLC who were treated with SBRT using a CyberKnife® from August 2010 to June 2019 were identified and included in this study. Local control (LC), local progression-free survival (LPFS), progression-free survival (PFS), overall survival (OS), and late toxicity were evaluated. Potential risk factors associated with LC, LPFS, PFS, or OS were investigated by univariate analyses.

Results: Data of 96 patients were examined. The prescribed dose to the tumor was 54 Gy in 3 fractions in 91 patients and 60 Gy in 3 fractions in 5 patients. The median follow-up duration was 27 months. The 2-year LC, LPFS, PFS, and OS rates were 97%, 88%, 84%, and 90%, respectively. The T factor was significantly correlated with LC, LPFS, and PFS. The 2-year LC rate for patients with T1a/T1b and T1c/T2a disease was 100% and 90%, respectively (p < 0.05), and the 2-year PFS rate for the corresponding patients was 95% and 65%, respectively (p < 0.001). One patient (1%) developed grade 3 radiation pneumonitis.

Conclusions: High-dose SBRT using a CyberKnife® for stage I peripheral NSCLC produced favorable treatment outcomes with acceptable late toxicity. Further studies are needed to improve the treatment outcomes for patients with T1c/T2a disease.

Keywords: Early-stage lung cancer, CyberKnife, Stereotactic body radiotherapy, Local control, Radiation pneumonitis

Background
Lung cancer is the leading cause of cancer mortality worldwide [1, 2]. Surgery is the gold standard treatment for early-stage non-small cell lung cancer (NSCLC) [3]. However, some patients may be unable to tolerate surgery because of old age, poor organ function, and/or concomitant illnesses. Stereotactic body radiotherapy (SBRT) is a high-precision radiotherapy technique that uses multiple beams from several directions to target a solitary tumor, enabling administration of a very high radiation dose to the tumor while minimizing doses to the surrounding normal tissues. Based on the results of several clinical studies conducted in Japan and North America [4–6], SBRT using a high-dose hypofractionation regimen is...
a viable option for patients with inoperable early-stage peripheral NSCLC [3].

Various types of radiotherapy machines and radiotherapy delivery techniques of SBRT for lung tumors have recently been developed. Linear accelerator-based SBRT (Linac-SBRT) is used worldwide and has produced favorable treatment results for early-stage NSCLC [4–7]. The CyberKnife® (CK) (Accuray, Sunnyvale, CA, USA) is another specialized machine for delivering robotic stereotactic radiotherapy that allows highly conformal irradiation with tumor motion tracking [8]. Several reports have described the efficacy and safety of CK-based SBRT (CK-SBRT) for early-stage NSCLC [9–12].

Although several studies of SBRT for early-stage NSCLC have shown promising treatment results, these studies used various dose-fractionation schedules. Several multi-institutional prospective studies of Linac-SBRT adopted a dose of 48 Gy in four fractions or 54 Gy in three fractions [4–6], and several CK-SBRT studies used a dose of 45, 54, or 60 Gy in three fractions [9–12]. Therefore, the optimal dose-fractionation regimen to maximize tumor control and minimize toxicity has not been determined.

Although SBRT can reduce the normal lung volume irradiated with high-dose versus conventional three-dimensional conformal radiotherapy, a high radiation dose with a hypofractionated schedule may cause severe lung toxicity. CK-SBRT may minimize the normal lung volume irradiated with high-dose versus Linac-SBRT [13], which may allow for safer radiation delivery to the lung. For these reasons, we have treated patients with early-stage peripheral NSCLC using CK-SBRT with 54 or 60 Gy in three fractions. The present study was performed to evaluate the efficacy and safety of this treatment and investigate the risk factors for recurrence.

Methods

Patients

The study cohort comprised patients with NSCLC treated with SBRT alone using a CK at our institute. The inclusion criteria were (1) stage I NSCLC according to the eighth version of the Union for International Cancer Control staging system, (2) a European Cooperative Oncology Group performance status of 0 or 1, (3) either pathologically or clinically diagnosed NSCLC, and (4) medically inoperable disease or patient refusal to undergo surgery. All patients underwent computed tomography (CT) scans of the chest and abdomen, 18F-fluorodeoxyglucose positron emission tomography, and magnetic resonance imaging of the brain prior to treatment. Bronchoscopy and biopsy/cytology of the tumor were performed when feasible. When bronchoscopy was not feasible because of poor respiratory/cardiac function and/or patient refusal, respiratory oncologists made a clinical diagnosis based on the progression of the radiological findings. The indications for SBRT were determined at multidisciplinary conferences comprising respiratory surgeons, medical oncologists, diagnostic radiologists, and radiation oncologists. Patients with central lung cancer, which was defined as a lesion within 2 cm of the main bronchus and/or within 1 cm of the heart, great vessels, esophagus, trachea, or brachial plexus, were excluded from the study. Patients with active interstitial pneumonia, serious comorbidities, or active double cancer were also excluded. This study was approved by our institutional review board (No. 18-132).

Radiotherapy

Patients underwent CT scans at 1.25-mm thickness using a LightSpeed Xtra® (GE Healthcare, Chicago, IL, USA). An Esform Vacuum Bag® (Engineering System Co., Ltd., Nagano, Japan) was used for patient immobilization. Four-dimensional chest CT scans at 2.5-mm thickness were performed to evaluate tumor respiratory motion. When the tumor respiratory motion was greater than 10 mm, two or three fiducial markers (Gold Marker®, Olympus, Tokyo, Japan) were placed near the tumor with a bronchoscope and four-dimensional CT.

The gross tumor volume (GTV) was defined as the visible tumor in the lung window on the treatment planning CT images, and the clinical target volume was defined as the same volume. For patients whose tumor respiratory motion was less than 10 mm, the internal target volume (ITV) was created with maximum intensity projection methods to cover the tumor in all respiratory phases. For patients whose tumor respiratory motion was greater than 10 mm, four-dimensional CT was performed using a 320-multidetector CT scanner (Aquilion ONE®, Canon Medical Systems, Otawara, Japan), and the ITV margin to compensate for the motion error between the GTV and the fiducial marker was added to the GTV. The planning target volume was determined by adding a 2-mm safety margin in all directions to the ITV. The organs at risk (brachial plexus, trachea and main bronchus, esophagus, heart and great vessels, lung fields, ribs, and spinal cord) were contoured on the planning CT images using the soft tissue window. Treatment plans were calculated using a ray-tracing algorithm until 2015 and a Monte Carlo algorithm after 2015. A total of 54–60 Gy in three fractions was prescribed to 70–80% isodose line encompassing 99% of GTV and 95% of PTV. Theoretical basis of prescription to GTV was described in the study from Miura et al. [14].

SBRT was delivered with 6-MV X-rays using CK G3™ technology with a fixed cone. When the tumor respiratory motion was less than 10 mm, the Xsight Spine...
Tracking System was used. This allowed the position of the tumor to be assessed and corrected on the basis of its location relative to the spine. When the tumor respiratory motion was greater than 10 mm, the Synchrony respiratory tracking system was used, meaning that the radiation beams were moved synchronously with the fiducial markers to match the movement of the lung tumor. We did not have the Synchrony Xsight Lung Tracking System (the direct lung tumor tracking system) in our CK system. Dose constraints for organs at risk were as follows: normal lung volume receiving more than 20 Gy ($V_{20Gy}$), < 15%; maximum dose ($D_{max}$) to the spinal cord, < 21.9 Gy; $D_{max}$ to the heart, < 30 Gy; minimum dose to the most irradiated 15 cm$^3$ of the heart, < 24 Gy; $D_{max}$ to the great vessels, < 45 Gy; $D_{max}$ to the bronchus, < 23.1 Gy; and $D_{max}$ to the trachea, < 30 Gy.

**Follow-up**

After completing the treatment, all patients were followed up every 1 to 3 months for the first year and every 4 to 6 months thereafter. All patients underwent a physical examination, blood tests including measurement of serum carcinoembryonic antigen and/or squamous cell carcinoma-related antigen, chest radiographs, CT scans.
of the chest and abdomen, and brain magnetic resonance imaging to evaluate the disease status and late toxicities. When recurrence was suspected, 18F-fluorodeoxyglucose positron emission tomography and, if feasible, biopsy/cytology were performed to determine the disease status. Treatment failures were classified as local recurrence, pulmonary hilar and/or mediastinal lymph node metastasis, or distant metastasis. Late toxicities were graded in accordance with the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 [15].

**Table 1** Patient and treatment characteristics

| Characteristic | Median (Range) |
|----------------|----------------|
| Age, years     | 77 (39–93)     |
| Sex, n (%)     |                |
| Male           | 61 (64)        |
| Female         | 35 (36)        |
| Operability, n (%) |            |
| Operable       | 25 (26)        |
| Inoperable     | 71 (74)        |
| Histological type, n (%) |         |
| Adenocarcinoma | 15 (16)        |
| Squamous cell carcinoma | 4 (4) |
| Not identified | 77 (80)        |
| T factor, n (%) |                |
| T1a            | 14 (15)        |
| T1b            | 47 (49)        |
| T1c            | 30 (31)        |
| T2a            | 5 (5)          |
| Dose prescription to GTV, n (%) | |
| 54 Gy in 3 fractions | 91 (95) |
| 60 Gy in 3 fractions | 5 (5) |
| Prescribed isodose line, %, median (range) | 76 (60–97) |
| V20Gy, %, median (range) | 2.4 (0.2–11.0) |
| GTV D99, %, median (range) | 101.4 (82.7–118.7) |
| PTV D95, %, median (range) | 95.6 (79.8–112.9) |

Data are presented as median (range) or n (%). GTV gross tumor volume, PTV planning target volume, V20Gy normal lung volume receiving more than 20 Gy.

**Table 2** Patterns of failure

| T factor (n) | Local recurrence | Regional recurrence | Distant metastasis |
|--------------|------------------|---------------------|-------------------|
| T1a/T1b (61) | 1                | 1                   | 4                 |
| T1c/T2a (35) | 4                | 5                   | 7                 |
| Total (96)   | 5                | 6                   | 11                |

**Statistical analysis**

Local control (LC) was defined as the interval between the date of initiation of therapy and the date of recurrence of the lung tumor or the most recent follow-up. Local progression–free survival (LPFS) was defined as the interval between the date of initiation of therapy and the date of recurrence of the lung tumor, death, or the most recent follow-up. Progression-free survival (PFS) was defined as the interval between the date of initiation of therapy and the date of disease progression, death, or the most recent follow-up. Overall survival (OS) was defined as the interval between the date of initiation of therapy and the date of death from any cause or the most recent follow-up. The actuarial LC, LPFS, PFS, and OS rates were calculated with the Kaplan–Meier method.

Potential risk factors associated with LC, LPFS, PFS, and OS were investigated by univariate analyses. Age, sex, T factor, history of pulmonary surgery, histological diagnosis, operability, and comorbidities were considered binary variables. Differences between two groups were compared using the log-rank test. A \( p \) value of <0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY, USA).

**Results**

Ninety-six patients with stage 1 NSCLC treated from August 2010 to June 2019 were identified and included in this study (Fig. 1). Nineteen patients were histologically diagnosed, and 77 patients were clinically diagnosed. The T stage distribution was as follows: T1a, 14 patients; T1b, 47; T1c, 30; and T2a, 5. Ninety-one patients received 54 Gy in three fractions, and the remaining five patients received 60 Gy in three fractions. Median prescribed isodose line was 76% (60–96%). Median GTV D99% was 101% (83–119%) of prescribed dose and median PTV D95% was 96% (80–113%) of prescribed dose (Table 1).

The duration of follow-up was 6 to 120 months (median, 27 months). During the follow-up period, 5 patients developed local recurrence; 6 developed regional lymph node metastases, including 2 hilar lymph nodes, 5 mediastinal lymph nodes, and 1 subclavian lymph node; and 11 developed distant metastases, including the lung, pleura, brain, bone, or adrenal gland. Most recurrences were observed in patients with T1c-T2 tumors (Table 2). At the last follow-up, six patients had died of lung cancer and four of other diseases. The 2- and 3-year rates of LC, LPFS, PFS, and OS for all patients
were 97% (95% confidence interval [CI] 93–100%) and 95% (95% CI 89–100%), 88% (95% CI 81–95%) and 86% (95% CI 79–94%), 84% (95% CI 76–92%) and 80% (95% CI 72–89%), and 90% (95% CI 83–97%) and 90% (95% CI 83–97%), respectively (Fig. 2a–d).

The univariate analysis showed that the T factor had a statistically significant impact on LC, PFS, LPFS, and OS (Table 3). The 2-year LC rate for patients with T1a/T1b and T1c/T2a disease was 100% and 90%, respectively \((p < 0.05)\), and the 2-year PFS rate was 95% and 65%, respectively \((p < 0.001)\) (Fig. 3a, b). Histological confirmation also showed a significant impact on LPFS and PFS outcomes, and patients without a histological diagnosis had better LPFS and PFS than those with a histological diagnosis (Table 3).

Regarding late toxicities, radiation pneumonitis occurred in 74 patients (77%), including grade 1 in 68 patients (71%), grade 2 in 5 patients (5%), and grade 3 in 1 patient (1%). The median interval between SBRT and the onset of radiation pneumonitis was 3 months (range 0–9 months). The patient who developed grade 3 radiation pneumonitis had simultaneous bacterial pneumonia, which may have worsened the pulmonary toxicity. No other grade 2 or higher late adverse events were observed.

**Discussion**

The efficacy and toxicity of CK-SBRT for stage I peripheral NSCLC were retrospectively evaluated. In this study, a 54–60 Gy in three fractions was prescribed to 76% (60–96) isodose line encompassing 99% of GTV. The 2- and 3-year LC rates for all patients were 97% and 95%, respectively. The corresponding OS rates were 90% and 90%, respectively (Fig. 2a, d).

In SBRT for early-stage NSCLC, various dose and fractionation schedules have been used, and the optimal dose-fractionation regimen to maximize tumor control and minimize toxicity has not yet been determined. To compare different dose-fractionation regimens, radiation doses are converted to biologically effective doses (BEDs) by the linear quadratic model using an alpha/beta ratio of 10 Gy for tumors [16]. The BEDs of 48 Gy in four fractions, 54 Gy in three fractions, and 60 Gy in
Table 3 Results of univariate analysis for LC, PFS, OS, and LPFS

| Characteristics                  | Patients (n) | 2-year LC (%) | p value | 2-year PFS (%) | p value | 2-year OS (%) | p value | 2-year LPFS (%) | p value |
|----------------------------------|--------------|---------------|---------|----------------|---------|---------------|---------|-----------------|---------|
| Age (years)                      |              |               |         |                |         |               |         |                 |         |
| > 75                             | 45           | 97            | 0.822   | 83             | 0.793   | 85            | 0.454   | 86              | 0.663   |
| ≤ 75                             | 51           | 96            | 0.815   | 75             | 0.052   | 86            | 0.353   | 84              | 0.684   |
| Sex                              |              |               |         |                |         |               |         |                 |         |
| Male                             | 61           | 95            | 0.044   | 95             | <0.001  | 98            | <0.001  | 98              | <0.001  |
| Female                           | 35           | 100           | 0.939   | 82             | 0.883   | 88            | 0.689   | 85              | 0.841   |
| T classification                 |              |               |         |                |         |               |         |                 |         |
| T1a/T1b                          | 61           | 100           | 0.277   | 67             | 0.002   | 89            | 0.123   | 79              | 0.049   |
| T1c/T2a                          | 35           | 96            | 0.226   | 85             | 0.786   | 96            | 0.747   | 96              | 0.411   |
| History of lung surgery          |              |               |         |                |         |               |         |                 |         |
| Yes                              | 29           | 96            | 0.128   | 92             | 0.402   | 90            | 0.920   | 90              | 0.497   |
| No                               | 67           | 97            | 0.939   | 82             | 0.883   | 88            | 0.689   | 85              | 0.841   |
| History of ischemic heart disease|              |               |         |                |         |               |         |                 |         |
| Yes                              | 24           | 100           | 0.226   | 85             | 0.786   | 96            | 0.747   | 96              | 0.411   |
| No                               | 72           | 95            | 0.277   | 67             | 0.002   | 89            | 0.123   | 79              | 0.049   |
| Histological diagnosis           |              |               |         |                |         |               |         |                 |         |
| Yes                              | 21           | 88            | 0.226   | 85             | 0.786   | 96            | 0.747   | 96              | 0.411   |
| No                               | 75           | 90            | 0.277   | 67             | 0.002   | 89            | 0.123   | 79              | 0.049   |
| Operability                      |              |               |         |                |         |               |         |                 |         |
| Operable                         | 25           | 100           | 0.128   | 92             | 0.402   | 90            | 0.920   | 90              | 0.497   |
| Inoperable                       | 71           | 95            | 0.226   | 85             | 0.786   | 96            | 0.747   | 96              | 0.411   |

LC local control, PFS progression-free survival, OS overall survival, LPFS local progression-free survival

Three fractions are 105 Gy$_{10}$, 151 Gy$_{10}$, and 180 Gy$_{10}$ respectively.

Several clinical studies have focused on SBRT for early-stage NSCLC using Linac-SBRT. In the JCOG0403 study, patients were treated with a dose of 48 Gy in four fractions at the isocenter of the tumor. The study demonstrated 3-year LC and OS rates of 87.3% and 59.9%, respectively, for patients with inoperable tumors and 85.4% and 76.5%, respectively, for patients with operable tumors [5]. In the RTOG0236 and 0618 studies, patients were delivered a dose of 54 Gy in three fractions to 95% of the planning target volume. The 3-year LC and OS rates were 97.6% and 55.8%, respectively, for patients with inoperable tumors (RTOG0236) [4]. The 4-year corresponding rates were 96% and 56%, respectively, for patients with operable tumors (RTOG0618) [6]. Several CK-SBRT studies used a dose of 45, 54, or 60 Gy in three fractions and reported that the 2- or 3-year LC and OS rates were 78% to 96% and 37% to 87%, respectively (Table 4). These reports suggest that the current study yielded favorable treatment outcomes comparable to or somewhat superior to those in the other studies, although our patient population included both patients with medically inoperable tumors and those who refused to undergo surgery.

Regarding the dose–response relationship in SBRT for early-stage NSCLC, several studies have demonstrated that a BED of $\geq$ 100 Gy$_{10}$ delivered at the isocenter of the tumor produced better LC and OS outcomes than a BED of < 100 Gy$_{10}$ [17, 18]. However, whether a higher BED (100–150 Gy$_{10}$ or $\geq$ 150 Gy$_{10}$) may contribute to better LC outcomes than a BED of 100 Gy$_{10}$ remains controversial. In their meta-analysis involving 2587 patients with stage I NSCLC, Zhang et al. [19] reported no significant relationship for LC among patients who received a low dose (< 83.2 Gy$_{10}$), medium dose (83.2–106 Gy$_{10}$), medium to high dose (106–146 Gy$_{10}$), and high dose (> 146 Gy$_{10}$). In contrast, Mehta et al. [18] analyzed the relationship between LC and BED in a systematic review and reported a positive dose–response relationship beyond a BED of 100 Gy$_{10}$ and 90% LC probability was achieved with a BED of $> 159$ Gy$_{10}$. More recently,
Stephans et al. [20] reported that a BED of 150 to 180 Gy$_{10}$ was associated with a lower rate of local failure than a BED of 100 Gy$_{10}$. From these results and the findings of the current study, additional randomized trials comparing SBRT regimens with BEDs ranging from 100 to 180 Gy$_{10}$ may be needed to determine the optimum dose to maximize the LC probability.

In the current study, the T factor was a significant factor impacting LC, LPFS, PFS, and OS outcomes as shown in the univariate analysis, and patients with T1a/T1b disease had significantly better outcomes than those with T1c/T2a disease.
T1c/T2a disease (Table 3). Although 90% of the patients with T1c/T2a disease achieved LC, six (17%) patients developed regional lymph node recurrence and/or distant metastasis (Table 2). Several studies demonstrated similar results in patients with T2 disease [20, 21]. Therefore, patients with T1c/T2 disease may require adjuvant treatments to prevent regional recurrence and/or distant metastasis. Several clinical studies are currently underway to evaluate the efficacy of adjuvant therapy using immune checkpoint inhibitors [22, 23].

Several studies showed that the incidence of grade 3 or higher radiation pneumonitis ranged from 2 to 9% in patients treated with Linac-SBRT or CK-SBRT [4, 5, 10–12, 24]. In the present study, only one (1%) patient developed grade 3 radiation pneumonitis. CK-SBRT enables highly concentrated dose distributions superior to those of Linac-SBRT. Several dosimetric studies have also suggested that CK-SBRT may have a dose concentration superior to that of Linac-SBRT [14, 25]. The tracking system of CK-SBRT also enables a reduction of the irradiated volume of the normal lung. These two aspects may have resulted in the low incidence of pulmonary toxicity in our study. In our patient population, the median $V_{20Gy}$ was only 2.4% (Table 1).

In the current study, the 2-year PFS and LPFS were better in patients without than with a histological diagnosis (Table 3). Several other reports have also indicated that patients without a histological diagnosis had better treatment outcomes [26]. We made the utmost efforts to confirm the histological diagnosis for all patients; however, this was difficult in some cases.

The current study has several limitations. First, because it was a retrospective single-institutional study, selection bias is possible. Second, few patients developed local recurrence, which may have limited the statistical reliability. Third, this study included patients with clinical diagnoses, which may have impacted the treatment outcomes. However, CK-SBRT treatment planning was uniformly performed, and recording and reporting of the dose-volume histogram parameters were in strict compliance with published guidelines. Furthermore, almost all patients were strictly followed up. The present study therefore provides useful information on treatment. A long-term follow-up study is

### Table 4 Studies involving Linac-SBRT and CK-SBRT for early-stage NSCLC

| Study                        | T1 (n)   | T2 (n)   | LC (%) | OS (%) | Dose     | Prescription | Lung toxicity |
|------------------------------|----------|----------|--------|--------|----------|--------------|--------------|
| **Linac-SBRT**               |          |          |        |        |          |              |              |
| Timmerman et al. [4]         | T1 (44)  |          | 3-year: 97.6 | 3-year: 55.8 | 54 Gy/3 Fr | PTV D95      | Grade 3: 4%   |
| Nagata et al. [5]            | T1 (169) | Operable | 3-year: 85.4 | 3-year: 76.5 | 48 Gy/4 Fr | Isocenter    | Operable      |
|                             |          | Inoperable | 3-year: 87.3 | 3-year: 59.9 |          |              |              |
| Koshy et al. [21]            | T1 (334) | NA       | 3-year: 50  | 5-year: 30 | 48–60 Gy/3–4 Fr | NA          | NA           |
| Matsuo et al. [25]           | T1 (73)  |          | 3-year: 86.8 | 3-year: 58.6 | 48 Gy/4 Fr | Isocenter    | Grade 3: 3%   |
|                             | T2 (28)  |          | 5-year: 46.7 |          |          |              |              |
| **CK-SBRT**                  |          |          |        |        |          |              |              |
| Bahig et al. [10]            | T1 (123) |          | 2-year: 96 | 2-year: 87 | 40–60 Gy/3–5 Fr | PTV D95 | Grade 3: 1%   |
|                             | T2 (27)  |          |        |        |          | 75% isodose  | Grade 5: 2% (with IPF) |
| Heal et al. [11]             | T1 (63)  |          | 2-year: 94 | 3-year: 37 | 50–60 Gy/3–5 Fr | NA          | Grade 3: 2%   |
|                             | T2 (37)  |          | 3-year: 84 |          |          |              |              |
| van der Voort van Zyp et al. | T1 (39)  |          | 2-year | 1-year: 83 | 45 or 60 Gy/3 Fr | PTV D95 | Grade 3: 4%   |
|                             | T2 (31)  |          |        | 2-year: 62 |          | 70–85% isodose |              |
|                             |          |          | 45 Gy: 78 | 60 Gy: 96 |          |              |              |
| Present study                | T1a/b (61) |          | 2-year: 97 | 2-year: 90 | 54–60 Gy/3 Fr | GTV D90 | Grade 3: 1%   |
|                             | T1c (30) |          |        |        |          | 70–80% isodose |              |
|                             | T2 (5)   |          |        |        |          |              |              |

Linac-SBRT linear accelerator-based stereotactic body radiotherapy, CK-SBRT CyberKnife®-based stereotactic body radiotherapy, NSCLC non-small cell lung carcinoma, PTV planning target volume, NA not available, IPF idiopathic pulmonary fibrosis, GTV gross tumor volume, Fr fractions
needed to confirm the efficacy and late toxicity of this treatment.

Conclusions
High-dose CK-SBRT for stage I peripheral NSCLC produced favorable treatment outcomes with acceptable late toxicity. Further studies are needed to improve the treatment outcomes for patients with T1c/T2a disease.

Abbreviations
BED: Biologically effective dose; CI: Confidence interval; CK: CyberKnife®; CT: Computed tomography; Dmax: Maximum dose; GTV: Gross tumor volume; ITV: Internal target volume; JCOG: Japan Clinical Oncology Group; LC: Local control; Linac-SBRT: Linear accelerator-based stereotactic body radiotherapy; LPFS: Local progression-free survival; NSCLC: Non-small cell lung cancer; OS: Overall survival; PFS: Progression-free survival; RTOG: Radiation Therapy Oncology Group; SBRT: Stereotactic body radiotherapy; V20Gy: Normal lung volume receiving more than 20 Gy.

Acknowledgements
We thank Angela Morben, DVM, ELS, from Edanz (https://jpedanz.com/ac), for editing a draft of this manuscript.

Author contributions
YR and TA designed the study. YR, TA, MI, SS, TA, TO, MI, RH, YK, KK, HK, HI, SN, and SK contributed to the acquisition and analysis of data. YR, TA, MI, and SK created the manuscript. All authors read and approved the final manuscript.

Funding
The authors received no funding specifically for this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of the International Medical Center, Saitama Medical University (Reference number: 18-132).

Consent for publication
Informed consent for publication was obtained from all patients in this study.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Radiation Oncology, International Medical Center, Saitama Medical University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. 2Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan. 3Department of General Thoracic Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan.

Received: 19 May 2022 Accepted: 29 June 2022
Published online: 19 July 2022

References
1. Cheng TY, Cramb SM, Baade PD, Youliden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11:1653–71.
2. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl 5):e15-e295.
3. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, version 3.2020, NCCN clinical practice guidelines in oncology. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed 28 Apr 2022.
4. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.
5. Nagata Y, Hiraoka M, Shibata T, Onishi H, Kobukuro M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer. Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989–96.
6. Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018;4:1263–6.
7. Zheng X, Schipper M, Kidwell K, Lim J, Reddy R, Ren Y, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90:6063–11.
8. Nuyttens JJ, van de Pol M. The CyberKnife radiosurgery system for lung cancer. Expert Rev Med Devices. 2012;9:465–75.
9. Temming S, Kocher M, Stoelben E, Hagemeyer L, Chang DH, Frank K, et al. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small cell lung cancer. Strahlenther Onkol. 2018;194:91–7.
10. Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, et al. Excellent cancer outcomes following patient-adapted robotic lung SBRT but a case for caution in idiopathic pulmonary fibrosis. Technol Cancer Res Treat. 2015;14:667–76.
11. Heal C, Ding W, Lamond J, Wong M, Lanciano R, Su S, et al. Definitive treatment of early-stage non-small cell lung cancer with stereotactic ablative body radiotherapy in a community cancer center setting. Front Oncol. 2015;5:146.
12. der Voort Van, van Zyp NC, Prévost JB, Hoogeman MS, Praag J, van der Holt B, Levendag PC, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91:296–300.
13. Atalar B, Aydin G, Gungor G, Caglar H, Yapici B, Ozvar E. Dosimetric comparison of robotic and conventional linear-accelerator-based stereotactic lung irradiation in early-stage lung cancer. Technol Cancer Res Treat. 2012;11:249–55.
14. Miura H, Masai N, Oh RJ, Shiomi H, Sasaki J, Inoue T. Approach to dose definition to the gross tumor volume for lung cancer with respiratory tumor motion. J Radiat Res. 2013;54:140–5.
15. National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 28 Apr 2022.
16. Jones B, Dale RG, Deehan C, Hopkins KJ, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol). 2001;13:71–81.
17. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–31.
18. Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol. 2012;2:288–95.
19. Zhang J, Yang F, Li B, Li H, Liu J, Huang W, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2011;81:305–16.
20. Stephens KL, Woody NW, Reddy CA, Varley M, Magnelli A, Zhuang T, et al. Tumor control and toxicity for common stereotactic body radiation therapy dose-fractionation regimens in stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;100:462–9.
21. Koshy M, Malik R, Weischelbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing...
stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;91:344–50.

22. AstraZeneca. Durvalumab vs placebo with stereotactic body radiation therapy in early stage unresected non-small cell lung cancer patients (PACIFIC-4). https://clinicaltrials.gov/ct2/show/NCT03833154. Accessed 28 Sept 2021.

23. Merck Sharp & Dohme Corp. Efficacy and safety study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab (MK-3475) in adults with medically inoperable stage I or IIA non-small cell lung cancer (NSCLC) (MK-3475-867/KEYNOTE-867). https://clinicaltrials.gov/ct2/show/NCT03924869. Accessed 28 Sept 2021.

Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki T, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79:1104–11.

25. Fowler JF, Tomé WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004;60:1241–56.

26. Ijsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg KCA, Lebenthal A, et al. Survival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis. J Thorac Oncol. 2019;14:583–95.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.